Kite Pharma: Kite to present CAR Tcell therapy portfolio across a spectrum of blood cancers during the 66th ASH meeting

Kite, a Gilead Company, will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T─cell therapy portfolio across a spectrum of blood cancers during the 66th American